Berlakovich G A, Imhof M, Karner-Hanusch J, Gotzinger P, Gollackner B, Gnant M, Hanelt S, Laufer G, Muhlbacher F, Steininger R
Department of Transplant Surgery, University of Vienna, Austria.
Transplantation. 1996 Feb 27;61(4):554-60. doi: 10.1097/00007890-199602270-00007.
Despite major advances in immunopharmacology, virtually all patients receive the same center-specific immunosuppressive regimen following orthotopic liver transplantation (OLT). The present analysis was performed on the hypothesis that the original disease representing the indication for OLT leads to a different initial immunological situation of the patient. The type of original disease might therefore be a predisposing factor for acute rejection episodes and influence graft and patient survival. From January 1988 to July 1994, 34 patients received OLT at our institution for end-stage primary biliary cirrhosis (group 1) and 66 patients for end-stage alcoholic cirrhosis (group 2). Overall survivals at 1 and 5 years in group 1 versus group 2 were 67% versus 80% and 50% versus 68%, respectively (P<0.04). Retransplantation was performed in 21% of patients from group 1 and in 6% from group 2. The estimated risk for freedom from acute rejection amounts to 38% in group 1 compared with 59% in group 2 (P<0.02). Multivariate regression analysis of potential risk factors identified only the underlying disease as independent predictor. Analysis of cumulative rates of clinically relevant rejection episodes stratified by group revealed 0.29 and 0.05 episodes per patient at one month and 0.80 and 0.06 at six months (P<0.009) respectively. In our clinical experience it was possible to confirm the hypothesis that the underlying disease is the reason for a significantly different incidence of acute rejection episodes and that it subsequently influences graft and patient survival. This approach to an individually adapted immunosuppressive therapy should be taken into consideration and other appropriate parameters investigated.
尽管免疫药理学取得了重大进展,但在原位肝移植(OLT)后,几乎所有患者都接受相同的中心特异性免疫抑制方案。本分析基于这样的假设进行:代表OLT适应证的原发病会导致患者初始免疫状态不同。因此,原发病的类型可能是急性排斥反应发作的一个诱发因素,并影响移植物和患者的存活。1988年1月至1994年7月,34例患者在我院接受OLT治疗终末期原发性胆汁性肝硬化(第1组),66例患者接受OLT治疗终末期酒精性肝硬化(第2组)。第1组与第2组1年和5年的总体生存率分别为67%对80%和50%对68%(P<0.04)。第1组21%的患者进行了再次移植,第2组为6%。第1组无急性排斥反应的估计风险为38%,而第2组为59%(P<0.02)。对潜在风险因素的多因素回归分析仅确定潜在疾病为独立预测因素。按组分层分析临床相关排斥反应发作的累积发生率显示,1个月时每位患者分别为0.29次和0.05次,6个月时为0.80次和0.06次(P<0.009)。根据我们的临床经验,可以证实这样的假设:潜在疾病是急性排斥反应发作发生率显著不同的原因,并且随后影响移植物和患者的存活。应考虑这种针对个体调整免疫抑制治疗的方法,并研究其他合适的参数。